文献速递急性肾损伤

N-乙酰半胱氨酸对血清肌酐和胱抑素C检测影响的系统综述

A Systematic Review of the Effect of N-Acetylcysteine on Serum Creatinine and Cystatin C Measurements.
PubMed 文献 · Kidney Int Rep · 2020-12-03

该系统综述纳入6项研究共199例参与者,评估NAC给药后血清肌酐和胱抑素C的变化。结果显示NAC后血清肌酐小幅但显著下降(WMD -2.80 μmol/L,P=0.05),而胱抑素C无变化,提示分析干扰而非肾功能改善。非Jaffe法和静脉给药亚组下降更明显。

要点

  • NAC可使血清肌酐小幅下降,但胱抑素C不变,提示检测干扰而非肾功能改变。
  • 非Jaffe法及静脉NAC亚组肌酐下降更显著,Jaffe法无显著变化。
  • 使用静脉高剂量NAC时,酶法检测肌酐可能低估或延迟诊断急性肾损伤。

核心结论

  • NAC导致血清肌酐下降而胱抑素C无变化,提示分析干扰而非对肾功能的影响。
  • 非Jaffe法肌酐检测下NAC的影响更大,支持检测干扰机制。

研究设计与样本

  • 系统综述与荟萃分析,纳入6项研究共199例参与者。
  • 主要结局为NAC给药后血清肌酐变化,次要结局为胱抑素C变化。

主要发现

  • NAC后血清肌酐总体小幅显著下降(WMD -2.80 μmol/L,95%CI -5.6至0.0,P=0.05)。
  • 非Jaffe法肌酐下降更明显(WMD -3.24 μmol/L,95%CI -6.29至-0.28,P=0.04),Jaffe法无显著变化(WMD -0.51 μmol/L,95%CI -7.56至6.53,P=0.89)。
  • 静脉NAC后肌酐下降显著(WMD -31.10 μmol/L,95%CI -58.37至-3.83,P=0.03),口服NAC无显著变化(WMD -2.5 μmol/L,95%CI -5.32至0.32,P=0.08)。
  • NAC给药后胱抑素C无变化。

临床怎么用

  • 未来报告肾脏结局的NAC研究应使用Jaffe法检测肌酐。
  • 临床使用高剂量静脉NAC时,酶法检测肌酐可能导致急性肾损伤漏诊或延迟诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: N-acetylcysteine (NAC) is an antioxidant that can regenerate glutathione and is primarily used for acetaminophen overdose. NAC has been tested and used for preventing iatrogenic acute kidney injury or slowing the progression of chronic kidney disease, with mixed results. There are conflicting reports that NAC may artificially lower measured serum creatinine without improving kidney function, potentially by assay interference. Given these mixed results, we conducted a systematic review of the literature to determine whether there is an effect of NAC on kidney function as measured with serum creatinine and cystatin C. METHODS: A literature search was conducted to identify all study types reporting a change in serum creatinine after NAC administration. The primary outcome was change in serum creatinine after NAC administration. The secondary outcome was a change in cystatin C after NAC administration. Subgroup analyses were conducted to assess effect of creatinine assay (Jaffe vs. non-Jaffe and intravenous vs. oral). RESULTS: Six studies with a total of 199 participants were eligible for the systematic review and meta-analysis. There was a small but significant decrease in serum creatinine after NAC administration overall (weighted mean difference [WMD], -2.80 μmol/L [95% confidence interval {CI} -5.6 to 0.0]; P = 0.05). This was greater with non-Jaffe methods (WMD, -3.24 μmol/L [95% CI -6.29 to -0.28]; P = 0.04) than Jaffe (WMD, -0.51 μmol/L [95% CI -7.56 to 6.53]; P = 0.89) and in particular with intravenous (WMD, -31.10 μmol/L [95% CI -58.37 to -3.83]; P = 0.03) compared with oral NAC (WMD, -2.5 μmol/L [95% CI -5.32 to 0.32]; P = 0.08). There was no change in cystatin C after NAC administration. DISCUSSION: NAC causes a decrease in serum creatinine but not in cystatin C, suggesting analytic interference rather than an effect on kidney function. Supporting this, the effect was greater with non-Jaffe methods of creatinine estimation. Future studies of NAC should use the Jaffe method of creatinine estimation when kidney outcomes are being reported. Even in clinical settings, the use of an enzymatic assay when high doses of intravenous NAC are being used may result in underdiagnosis or delayed diagnosis of acute kidney injury.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Huang JW, Lahey B, Clarkin OJ, et al. A Systematic Review of the Effect of N-Acetylcysteine on Serum Creatinine and Cystatin C Measurements. Kidney Int Rep. 2020. PMID: 33615065. doi:10.1016/j.ekir.2020.11.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。